Sign In
Buy HIMS
$28.01
+0.500 (+1.82%)
At Close: Jun 04, 2026
Telehealth Stock Looks Primed for a Short Squeeze
10:19am, Friday, 19'th Sep 2025
Subscribers to Schaeffer's Weekend Trader options recommendation service received this HIMS commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry a
Hims & Hers Health: Bumpy Ride Will End
02:57pm, Thursday, 18'th Sep 2025
Hims & Hers Health has traded very volatile over the last year as the market misunderstand the business opportunity beyond GLP-1s and weight-loss drugs. The online health and wellness faces FDA scruti
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
11:51am, Thursday, 18'th Sep 2025
The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.
Hims & Hers shares drop 6% after FDA warning on semaglutide marketing claims
02:03pm, Wednesday, 17'th Sep 2025
Hims & Hers Health Inc. (NYSE: HIMS) saw its stock fall 6% on Tuesday following the release of a warning letter from the US Food and Drug Administration (FDA) concerning marketing claims related to it
Trump Drug Ad Crackdown: FDA Warns Novo Nordisk, Eli Lilly, Hims
04:45pm, Tuesday, 16'th Sep 2025
The Food and Drug Administration sent warning letters to dozens of drug companies— including popular telehealth firm Hims & Hers and pharmaceutical giants Eli Lilly and Novo Nordisk— demanding the
FDA Warns Hims Over Ads About Compounded Weight-Loss Drugs
02:05pm, Tuesday, 16'th Sep 2025
The Food and Drug Administration sent warning letters to dozens of drug companies this month, including popular telehealth firm Hims & Hers, demanding they correct “false or misleading claims” abo
Hims & Hers shares drop 6% after FDA warning on semaglutide marketing claims
01:45pm, Tuesday, 16'th Sep 2025
Hims & Hers Health Inc. (NYSE: HIMS) saw its stock fall 6% on Tuesday following the release of a warning letter from the US Food and Drug Administration (FDA) concerning marketing claims related to it
Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy
01:26pm, Tuesday, 16'th Sep 2025
Hims & Hers Health Inc. HIMS stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims & Hers Health, dated Sept.
US FDA warns Hims & Hers over misleading claims on diabetes, weight-loss drugs
12:31pm, Tuesday, 16'th Sep 2025
The U.S. Food and Drug Administration has sent a warning letter to telehealth firm Hims & Hers Health regarding its compounded versions of Novo Nordisk's diabetes drug Ozempic and weight-loss treatmen
Huge News for Hims & Hers Stock
11:28am, Tuesday, 16'th Sep 2025
Hims & Hers (HIMS -7.84%) is adding another specialty in an effort to build out its healthcare platform. The company has brought testosterone to the market, the first big addition since weight loss in
Hims & Hers Expands AI and Technology Focus to Advance Digital Care
11:26am, Tuesday, 16'th Sep 2025
HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: Here's Why
06:46pm, Monday, 15'th Sep 2025
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $54.03, signifying a -2.65% move from its prior day's close.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
10:01am, Monday, 15'th Sep 2025
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
US FDA chief says Super Bowl ad by Hims & Hers 'breached' drug promotion rules
06:52pm, Friday, 12'th Sep 2025
U.S. Food and Drug Administration Commissioner Martin Makary said on Friday that Hims & Hers' Super Bowl advertisement breached federal law as it highlighted the benefits of weight-loss drugs without
Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?
11:05am, Friday, 12'th Sep 2025
HIMS accelerates with new men's health launches, global expansion plans and strong subscriber-driven growth, but rising costs strain gross margins.
